The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment
Paris, France
July 13-16, 2003
To see the complete index of our coverage for this conference, click here, or download the PDF version of our complete conference coverage (600K).
What were the top developments from IAS 2003? Judith Aberg, M.D., Cal Cohen, M.D., Robert Frascino, M.D., and Paul Sax, M.D., offer their opinions.
There may remain a small subset of patients for whom a three-NRTI regimen is appropriate, but given the high rates of failure relative to the efavirenz-containing arms of ACTG 5095, clinicians should think long and hard before using Trizivir or any other triple nucleoside combination alone. Brian Boyle, M.D., reports from IAS 2003.
The durability of T-20's benefit combined with its optimized background is similar to that of other effective salvage regimens. Read Andy Pavia, M.D.'s review.
A wide range of oral session Webcasts from Paris is available courtesy of kaisernetwork.org. Click here to browse through them!
The supply of T-20 is expected to be 50 percent greater by the end of this year than originally expected, according to David Reddy, head of drug maker Roche's HIV division.
Nearly one out of every 10 Europeans newly infected with HIV has a drug-resistant strain of the virus, according to results of a large study.
HIVers are dying less and less from HIV, but more and more from other complications -- like hepatitis C and injection drug use -- often related to the factors that put them at risk for HIV infection.
The United States plans to purchase low-cost generic antiretroviral drugs as part of President George W. Bush's global AIDS initiative, U.S. officials said at a press conference during IAS 2003.
Giving infants a daily dose of antiretroviral therapy from birth through the entire breastfeeding period could significantly lower their risk of contracting HIV through breast milk from their HIV-positive mothers.
The International AIDS Society has been coordinating the International AIDS Conferences every two years. They have added another conference in the years when the International AIDS conference is not held because they say science has been advancing so fast. This new event is smaller and devoted to basic and clinical science. For the complete program, click here.
Coverage Provided By:
Funding for coverage of this conference is provided, in part, by unrestricted educational grants from Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb Company, Gilead Sciences, GlaxoSmithKline and Ortho Biotech.
Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.
